id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
26,,,,,,,,,,,,,,,2024-05-01T16:45:57+06:00,BSH - H12206256707,,Lapatinib + Capecitabine,2024-03-01,1.0,"Adjuvant ChT with 4 cycles of AC schedule from 28.04.20- 30.06.20 > 4 cycles of Docetaxel
ended on Sep 2020 @BRB> Xeloda for 4-5 days then admitted at ICU 2020 @SHL.
On 24.05.22 review from India, Adviced ChT with Nab pacli+ Trastuzumab from India, C1 received on
14.06.22, Completed C6 on 27.09.2022 @BSHL.
Started maintenance Trastuzumab on 18.10.22. M11 till May/23 > PD >
On TDM-1 260mg since 15/06/23, Cycle 4 received on 17.08.2023> Re-evaluated from India and plan to
continue Inj TDM1 200mg q3w, Cycle 6 due on 12.11.23 (Delayed due to thrombocytopenia and received
on 25.11.2023), C7 due on 17.12.2023 (Delayed due to thrombocytopenia and received on 21.12.2023)> PD
Now on Lapatinib + Capecitabine, C1 started from March 24, C2 delayed due to thrombocytopenia> C3
due on 21.04.2024 (delayed due to thrombocytopenia)",2024-03-01,,2024-04-20,,,,,Breast,23,Middle class,BSBSC-240000023,FARJANA HOQUE,1915749251,1981-07-02,Female,,,,,Dr Md Arifur Rahman,BSH,3.0,4th Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,"C50.9- Breast, unspecified",Breast,Left,,,Progressed,Alive,,,,,,,,,,,,,,,,,,,,,,
